Have a feature idea you'd love to see implemented?
Let us know!
ITOS iTeos Therapeutics Inc
Price (delayed)
$7.85
Market cap
$286.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.15
Enterprise value
$168.27M
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of
Highlights
iTeos Therapeutics's debt has decreased by 7% YoY
ITOS's equity is up by 6% YoY but it is down by 4.8% from the previous quarter
The company's net income has shrunk by 97% YoY and by 12% QoQ
The EPS has dropped by 83% year-on-year and by 5% since the previous quarter
Key stats
What are the main financial stats of ITOS
Market
Valuations
Earnings
Shares outstanding
36.53M
Market cap
$286.79M
Enterprise value
$168.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.45
Price to sales (P/S)
9.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.81
Revenue
$35M
Gross profit
$35M
Net income
-$121.25M
EBIT
-$112.17M
EBITDA
-$111.03M
Free cash flow
-$120.32M
Per share
Balance sheet
Liquidity
EPS
-$3.15
EPS diluted
-$3.15
Free cash flow per share
-$2.79
Book value per share
$17.3
Revenue per share
$0.81
TBVPS
$16.76
Total assets
$723.08M
Total liabilities
$91.39M
Debt
$5.53M
Equity
$631.69M
Working capital
$508.06M
Debt to equity
0.01
Current ratio
14.8
Quick ratio
14.26
Net debt/EBITDA
1.07
Margins
Efficiency
Dividend
EBITDA margin
-317.2%
Gross margin
100%
Net margin
-346.4%
Operating margin
-429.5%
Return on assets
-17.5%
Return on equity
-20.1%
Return on invested capital
-23.9%
Return on capital employed
-16.3%
Return on sales
-320.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ITOS stock price
How has the iTeos Therapeutics stock price performed over time
Intraday
2.48%
1 week
0.51%
1 month
2.21%
1 year
-30.71%
YTD
2.21%
QTD
2.21%
Financial performance
How have iTeos Therapeutics's revenue and profit performed over time
Revenue
$35M
Gross profit
$35M
Operating income
-$150.34M
Net income
-$121.25M
Gross margin
100%
Net margin
-346.4%
The company's net income has shrunk by 97% YoY and by 12% QoQ
The operating income has shrunk by 61% YoY and by 3.8% QoQ
iTeos Therapeutics's gross profit has decreased by 47% YoY
ITOS's revenue is down by 47% year-on-year
Growth
What is iTeos Therapeutics's growth rate over time
Valuation
What is iTeos Therapeutics stock price valuation
P/E
N/A
P/B
0.45
P/S
9.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.81
The EPS has dropped by 83% year-on-year and by 5% since the previous quarter
ITOS's P/B is 74% below its 5-year quarterly average of 1.7 and 37% below its last 4 quarters average of 0.7
ITOS's equity is up by 6% YoY but it is down by 4.8% from the previous quarter
ITOS's revenue is down by 47% year-on-year
Efficiency
How efficient is iTeos Therapeutics business performance
The ROE has plunged by 107% YoY and by 10% from the previous quarter
The ROA has plunged by 103% YoY and by 10% from the previous quarter
The ROIC has dropped by 88% year-on-year and by 2.6% since the previous quarter
The return on sales has declined by 9% since the previous quarter
Dividends
What is ITOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ITOS.
Financial health
How did iTeos Therapeutics financials performed over time
The current ratio has declined by 33% year-on-year and by 18% since the previous quarter
The quick ratio is down by 33% YoY and by 19% QoQ
iTeos Therapeutics's debt is 99% lower than its equity
iTeos Therapeutics's debt has decreased by 7% YoY
ITOS's equity is up by 6% YoY but it is down by 4.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.